Search results
Found 30386 matches for
Hughes Group: Genome Biology
MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine Nuffield Division of Clinical Laboratory Sciences
Using genomics, computational and synthetic biology approaches to understand how genes are regulated in health and disease.
Gill and Hyde Group: Gene Medicine Group
Nuffield Division of Clinical Laboratory Sciences
We are developing gene therapy for lung conditions, including the genetic disease Cystic Fibrosis (CF) and neonatal lung conditions such as surfactant protein B (SPB) deficiency. We are also evaluating whether the lung can be used as a ‘protein factory’ to make therapeutic proteins such as antibodies.
Ferreira Group: Quantitative cardiac magnetic resonance myocardial tissue characterisation
Division of Cardiovascular Medicine Oxford Centre for Clinical Magnetic Resonance Research
We have expertise in the study of heart disease using cardiovascular magnetic resonance (CMR), particularly quantitative techniques such as myocardial T1-mapping.
Adler Group: Diabetes Trials Unit
Oxford Centre for Diabetes, Endocrinology and Metabolism
The Diabetes Trials Unit (DTU) is a clinical trials unit specialising in performing local, national and multinational clinical trials related to treating and managing diabetes and other cardiometabolic and related conditions.
Betts Group: Cardiac Rhythm Management
Division of Cardiovascular Medicine
The CRM group’s principal research interests are the treatment of abnormal heart rhythms and the resynchronisation of abnormal electrical conduction in heart failure patients. There is a particular focus on the use of novel and emerging technologies.
Buchan Group: Laboratory of Cerebral Ischemia
Investigative Medicine Division
The Laboratory of Cerebral Ischemia is a pre-clinical research group aiming to discover both the mechanisms which underlie cell death in stroke and to develop novel strategies to reduce this.
Ashrafian Group: Experimental Therapeutics and Clinical Pharmacology
Division of Cardiovascular Medicine
Channon Group: Cardiovascular functional genomics and redox signalling
Division of Cardiovascular Medicine
We work to understand how early changes in cells of the cardiovascular system, such as endothelial cells and leukocytes, are related to cardiovascular disease, with a particular focus on redox biology.
Watkins Group: Inherited Heart Muscle Disease Group
Division of Cardiovascular Medicine
Using human genetics and functional genomics to understand inherited heart disease
Inherited Heart Disease Service
Division of Cardiovascular Medicine
We make about 1600 patient contacts a year with those who have, or are at risk of having, an Inherited Cardiac Condition (eg cardiomyopathies and inherited arrhythmias) across all age ranges. We provide cardiology screening (ECG, Echocardiography) and clinical genetics during an initial single clinic visit, and provide telephone and e-mail support throughout the working week. We have made internationally recognised contributions in this area, in particular the use of cardiac MRI in diagnosis, and understanding of the underlying genetic basis of Inherited Cardiac Conditions.
Leeson Group: Preventive Cardiology Research Group
Cardiovascular Clinical Research Facility Division of Cardiovascular Medicine
Our aim is to develop better ways to identify early disease and improve cardiovascular health for young people. This is achieved by undertaking work in three areas: (1) Identification of novel markers of early disease to better understand how disease becomes established (2) Performing cardiovascular prevention trials in young adults to understand how to modify early disease and improve health (3) Application of artificial intelligence to imaging and research datasets to identify next generation imaging and management approaches.
Banning Group
Division of Cardiovascular Medicine
Use of minimally invasive techniques to improve heart function.
Bhattacharya Group: Developing novel therapeutics for inflammatory diseases
Division of Cardiovascular Medicine
Our goals are to develop therapeutics targeting the chemokine network in inflammatory diseases affecting the heart, blood vessels and other organ systems.
Lygate Group: Cardiac Energetics and Integrative Physiology
Division of Cardiovascular Medicine
We study how the heart meets its high and variable energy demands in order to identify novel strategies that may be beneficial in disease.
Carnicer Group
Division of Cardiovascular Medicine
Nitric oxide regulation of cardiac function, metabolism and inflammation in diabetes.
Gehmlich group: Biomechanical stress signalling in the heart and its role in cardiomyopathies
Division of Cardiovascular Medicine
We research genetic diseases of the heart (cardiomyopathies) that can lead to sudden cardiac death. An example of an individual with cardiomyopathy is the professional football player Fabrice Muamba, who collapsed on the pitch and had to be resuscitated. He was fortunate to survive his cardiac arrest and his case was featured in the media.
Choudhury Group: Understanding Inflammatory processes in Atherosclerosis and Acute Myocardial Infarction
Acute Multidisciplinary Imaging and Interventional Centre Division of Cardiovascular Medicine
This translational science laboratory aims to understand the functionally important heterogeneity in human cardiovascular disease to allow stratification of pathology and enable targeted therapies.
Douglas Group: Functional coronary artery disease genetics
Division of Cardiovascular Medicine
Defining the function of new causal atherosclerosis genes from CAD GWAS loci using in vitro and in vivo models.
Casadei Group: Translational approaches in chronic cardiac disease
Division of Cardiovascular Medicine
Our programme of work aims to understand nitric oxide (NO) and redox signalling in healthy and diseased myocardium, with a particular focus on atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). Building on the resources and original discoveries that we have made recently, we plan to test novel interventions that aim to correct the myocardial substrate that promotes the new onset of AF, or HFpEF, or prevent the adverse atrial remodelling that is induced by AF.
Myerson Group: Heart Valve Disease
Division of Cardiovascular Medicine Oxford Centre for Clinical Magnetic Resonance Research
We investigate diseases of the heart valves – how widespread the problem is, what the causes are, who is at risk from future problems and what treatments can improve outcomes for patients.